(Press-News.org) (NEW YORK, NY, April 12, 2012) —Maintaining the right level of sugar in the blood is the responsibility not only of insulin, which removes glucose, but also of a hormone called glucagon, which adds glucose.
For decades, treatments for type II diabetes have taken aim at insulin, but a new study suggests that a better approach may be to target glucagon's sweetening effect.
The findings were published today in the online edition of Cell Metabolism.
"What we've found is a way to reduce glucagon's influence on blood sugar without the side effects of global glucagon repression," said Ira Tabas, MD, PhD, Richard J. Stock Professor and Vice Chair of Research in the Department of Medicine and professor of Anatomy & Cell Biology (in Physiology and Cellular Biophysics), who led the study with Lale Ozcan, PhD, associate research scientist.
Though glucagon was discovered at the same time as insulin, research on it has languished compared with that of its cousin, and treatments have almost exclusively targeted the latter.
In the last decade, the success of incretins, a new class of drugs for type II diabetes, has sparked a renaissance in glucagon research. When they were first introduced, incretins were known to stimulate insulin secretion. But recent studies show that a significant part of their clinical success can be attributed to previously unsuspected inhibiting effects on glucagon secretion.
The experience with incretin has led to a renewed search for other drugs that act against glucagon, including compounds that block glucagon in the liver, where it acts to free glucose. Drugs that block the glucagon receptor in the liver have been tested, but glucagon has multiple roles, and recent early clinical trials show that it can raise cholesterol and lead to fat accumulation in the liver.
The new study shows how glucagon's effect on glucose could be disrupted without disturbing glucagon's other duties, raising prospects for a safer anti-glucagon diabetes treatment.
Drs. Tabas and Ozcan found that once glucagon binds to its receptor, glucose is fully released only after an enzyme called CaMKII is activated. When activated, CaMKII sends a protein called FoxO1 into the cell nucleus, where it turns on the genes needed for glucose secretion. A related pathway, working in parallel to this one, sends a FoxO1 helper protein into the cell nucleus, as reported in a paper on which Dr. Tabas is a co-author, published online on April 8 in Nature (embargoed until that time).
"Even when their disease is well controlled, most patients with type II diabetes have excess glucagon action, so blocking CaMKII could potentially be a new way to lower blood sugar and better treat the disease," said Dr. Tabas.
When the researchers blocked CaMKII in obese, diabetic mice, the animals' blood sugar went down, with no negative side effects. Instead, cholesterol declined, insulin sensitivity improved, and the liver became less fatty.
"Until now, it has been difficult to block glucagon's effect on blood sugar without interfering with glucagon's other functions," said Dr. Tabas, "but we think CaMKII is different."
Dr. Tabas is now working on the possibility of developing a CaMKII inhibitor to treat diabetes.
INFORMATION:
Drs. Ozcan's and Tabas' paper is titled, "Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity." Domenico Accili, MD, Russell Berrie Foundation Professor of Diabetes (in Medicine) and a world-renowned diabetes expert, was a major contributor to this study.
Additional authors are: Catherine C.L. Wong (Scripps Research Institute); Gang Li (CUMC); Tao Xu (Scripps Research Institute); Utpal Pajvani (CUMC); Sung Kyu Robin Park (Scripps Research Institute); Anetta Wronska (CUMC); Bi-Xing Chen (CUMC); Andrew R. Marks (CUMC); Akiyoshi Fukamizu (University of Tsukuba, Japan); Johannes Backs (University of Heidelberg, Germany); Harold A. Singer (Albany Medical College); and John R. Yates, III (Scripps Research Institute).
The researchers declare no financial or other conflict of interest.
This work was supported by an American Heart Association Scientist Development Grant to L. Ozcan; Emmy Noether-DFG grant 2258/2-1 to J. Backs; and NIH grants P41 RR011823 to C.C.L. Wong and J. Yates III NHLBI Proteomic Centers grant HHSN268201000035C to T. Xu, HL49426 to H.A. Singer, HL087123 and DK057539 to D. Accili, and HL087123 and HL075662 to I. Tabas.
Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia's College of Physicians and Surgeons was the first institution in the country to grant the M.D. degree and is among the most selective medical schools in the country. Columbia University Medical Center is home to the largest medical research enterprise in New York City and state and one of the largest in the United States. For more information, please visit www.cumc.columbia.edu.
END
As ocean temperatures rise, some species of corals are likely to succeed at the expense of others, according to a report published online on April 12 in the Cell Press journal Current Biology that details the first large-scale investigation of climate effects on corals.
"The good news is that, rather than experiencing wholesale destruction, many coral reefs will survive climate change by changing the mix of coral species as the ocean warms and becomes more acidic," said Terry Hughes of James Cook University in Australia. "That's important for people who rely on the rich ...
Last week, Land Rover celebrated its 25 years in North America in style at the New York International Auto Show, where its Range Rover Evoque was named World Car Design of the Year 2012. Recognizing design innovation and bold style, the accolade is the 101st global award presented to the Evoque, which is currently available at Land Rover dealerships.
The 2012 Evoque emerged from a group of 46 nominated vehicles to take the World Car Design of the Year title. Open only to vehicles introduced to a major market in 2011 or early 2012, the award was ultimately determined ...
A study published online on April 12 in the Cell Press journal Current Biology offers some news for parents: even toddlers have a tendency to follow the crowd. That sensitivity isn't unique to humans either; chimpanzees also appear more likely to pick up habits if "everyone else is doing it."
That conclusion comes from evidence that 2-year-olds and chimpanzees are more likely to copy actions when they see them repeated by three of their peers than if they see the same action done by one peer three times.
"I think few people would have expected to find that 2-year-olds ...
Expanding on previous research providing proof-of-principal that human stem cells can be genetically engineered into HIV-fighting cells, a team of UCLA researchers have now demonstrated that these cells can actually attack HIV-infected cells in a living organism.
The study, published April 12 in the journal PLoS Pathogens, demonstrates for the first time that engineering stem cells to form immune cells that target HIV is effective in suppressing the virus in living tissues in an animal model, said lead investigator Scott G. Kitchen, an assistant professor of medicine ...
Imagine a world where the rooftops and pavements of every urban area are resurfaced to increase the reflection of the Sun's light rays. Well, this is exactly what a group of Canadian researchers have done in an attempt to measure the potential effects against global warming.
In a study published today, 13 April, in IOP Publishing's journal Environmental Research Letters, researchers from Concordia University created this scenario to see what effect a global increase in surface reflectance would have on global temperature and our own carbon dioxide (CO2) emissions.
They ...
The UK health insurance brand Health-on-Line offers a fresh approach to medical insurance - with low cost, simple to understand policies that customers can easily tailor to their needs with a selection of add-ons that boost cover where needed.
Bournemouth based Health-on-Line -which was recently acquired by AXA PPP healthcare - provides affordable private medical insurance for individuals, with a special Business Priority Health package for enterprise customers - from sole traders right up to large group schemes.
Health-on-Line have taken a fresh look at medical cover, ...
Researchers at the University of California, Davis have discovered a key tool that helps sperm and eggs develop exactly 23 chromosomes each. The work, which could lead to insights into fertility, spontaneous miscarriages, cancer and developmental disorders, is published April 13 in the journal Cell.
Healthy humans have 46 chromosomes, 23 from the sperm and 23 from the egg. An embryo with the wrong number of chromosomes is usually miscarried, or develops disorders such as Down's syndrome, which is caused by an extra copy of chromosome 21.
During meiosis, the cell division ...
Who will win the big prize? Fans of the new reality series "Fashion Star" on NBC can hardly wait to find out. This unique design show offers merchandizing contracts to each week's winners, with a $6,000,000 contract as the grand prize. The winning designs are available the next day in stores, using the Lilitab iPad kiosk at select Macy's.
Supermodel Elle Macpherson hosts the program with a panel of fashion mentors: Jessica Simpson, Nicole Richie and John Varvatos. Viewers get instant gratification, and the hottest new styles, by being able to purchase their ...
Two Massachusetts General Hospital (MGH)-based research teams, along with a group from the University of California at San Diego, have discovered that animals have a previously unknown system for detecting and responding to pathogens and toxins. In three papers published in the journals Cell and Cell Host & Microbe, the investigators describe finding evidence that disruptions to the core functions of animal cells trigger immune and detoxification responses, along with behavioral changes.
"Viewing many diseases through the prism of this newly discovered system will eventually ...
Chapel Hill, NC – In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases "en masse", enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.
Kinases are proteins expressed in human tissues that play a key role in cell growth, particularly in cancer. Of the 518 known human kinases, about 400 are expressed in cancers, but which ones and how many are actually active in tumors has ...
